Characteristics | Â |
---|---|
Age of recipient, years | Median: 46.5 (range: 20â74) |
Gender (male) N (%) | 57 (66%) |
Type of transplant N (%) | |
âKidney | 82 (95.4%) |
âKidney + pancreas | 4 (4.6%) |
Type of donor N (%) | |
âLiving | 8 (9.3%) |
âDeceased | 78 (90.7%) |
Pretransplant donor (D)/recipient (R) CMV serostatus N (%) | |
âD+/R- | 18 (20.9%) |
âDâ/R- | 1 (1.1%) |
âDâ/R+ | 8 (9.4%) |
âD+/R+ | 59 (68.6%) |
Induction therapy N (%) | |
âThymoglobulin | 7 (8.1%) |
âBasiliximab | 62 (72.1%) |
âNone | 17 (19.8%) |
Maintenance immunosuppression N (%) | |
âTacrolimus +mycophenolate mofetil + prednisone | 77 (89.5%) |
âTacrolimus + mycophenolate sodium + prednisone | 7 (8.1%) |
âCyclosprine Aâ+âmycophenolate mofetil + prednisone | 1 (1.2%) |
âTacrolimus + everolimus + prednisone | 1 (1.2%) |
The time of VGCV initiation (days), meanâ±âSD [range] | 9â±â4.7 [0â25] |
The time of VGCV discontinuation (days), meanâ±âSD [range] | 92.4â±â13.1 [53â122] |
Duration of antiviral prophylaxis (days), meanâ±âSD [range] | 83.1â±â13.4 [40â113] |
Tacrolimus concentration (ng/mL), meanâ±âSD [range] | |
âDay 30 | 10.4â±â3.7 [0.3â23] |
âDay 90 | 9.5â±â4.5 [0.3â25.2] |
âDay 360 | 7.4â±â2.8 [3.2â22.4] |
Allograft function (eGFR; mL/min/1.73 m2), meanâ±âSD [range] | |
âDay 30 | 48.7â±â21.9 [6.7â103.7] |
âDay 90 | 50.4â±â21.0 [8.5â98.9] |
âDay 360 | 51.3â±â20.4 [10.2â96.7] |